The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: A prospective cohort comparison

British Journal of Haematology

Volumn 101, Issue 4, 1998, Pages 632-637

  Hay, C R M ^a   Ludlam, C A ^b   Lowe, G D O ^c   Mayne, E E ^d   Lee, R J ^e   Prescott, R J ^e   Lee, C A ^f  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c GLASGOW ROYAL INFIRMARY   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

CD4; HIV infected haemophiliacs; Purified factor VIII concentrates

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; DISEASE COURSE; HELPER CELL; HEMOPHILIA A; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ION EXCHANGE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

BLOOD COMPONENT TRANSFUSION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; FACTOR VIII; HEMOPHILIA A; HIV INFECTIONS; HUMANS; ION EXCHANGE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0031803244     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00753.x     Document Type: Article

References (22)

1. Berntorp, E. (1994) Impact of replacement therapy on the evolution of HIV infection in haemophiliacs. Thrombosis and Haemostasis, 71, 678-683.
2. Concorde Coordinating Committee (1994) Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet, 343, 871-881.
3. Darby, S.C., Rizza, C.R., Doll, R., Spooner, R.J.D., Stratton, I.M. & Thakrar, J. (1989) Incidence of AIDS and excess of mortality associated with HIV in haemophiliacs in the United Kingdom: report on behalf of the directors of haemophilia centres in the United Kingdom. British Medical Journal, 298, 1064-1068.
4. De Biasi, R., Rocino, A., Miraglia, E., Mastrullo, L. & Quirino, A.A. (1991) The impact of very high purity factor VIII concentrate on the immune system of HIV infected hemophiliacs: a randomised prospective, 2 year comparison with intermediate purity concentrate. Blood, 78, 1919-1923.
5. Eyster, M.E., Gail, M.H., Ballard, J.O., Al-Mondhiry, H. & Goedert, J.J. (1987) Natural history of human immunodeficiency virus. Infections in haemophiliacs: effects of T-cell subsets, platelet counts and age. Annals of Internal Medicine, 107, 1-6.
6. Fischl, M.A., Richman, D.R., Hansen, N., Collier, A.C., Carey, J.T. & Para, M.F. (1990) The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Annals of Internal Medicine, 112, 723-737.
7. Goldsmith, J.M., Deutche, J., Tang, M. & Green, D. (1991) CD4 cells in HIV-1 infected haemophiliacs: effect of factor VIII concentrates. Thrombosis and Haemostasis, 66, 415-419.
8. Hay, C.R.M. & McEvoy, P. (1992) Purity of factor VIII concentrates. Lancet, 339, 1613.
9. Hilgartner, M.W., Buckley, J.J., Operskalski, E.A., Pike, M.C., Mosley, J.W., for the Transfusion Safety Study Group (1993) Purity of factor VIII concentrates and serial CD4 counts. Lancet, 341, 1373-1374.
10. Lee, C.A., Phillips, A., Elford, J., Miller, E.J., Bofill, M., Griffiths, P.D. & Kernoff, P.B.A. (1989) The natural history of human immunodeficiency virus in a haemophilic cohort. British Journal of Haematology, 73, 228-234.
11. Ludlam, C.A., Tucker, J. & Steel, C.M. (1985) Human lymphotropic virus type III (HTLV III) infection in seronegative patients after transfusion of factor VIII. Lancet, ii, 233-236.
12. Mannucci, P.M., Gringeri, A., De Biasi, R., Baudo, F., Morfini, M. & Ciavarella, N. (1992) Immune status of asymptomatic HIV-infected haemophiliacs: randomised comparison of treatment with high-purity with intermediate-purity factor VIII concentrate. Thrombosis and Haemostasia, 67, 310-313.
13. Menitove, J.E., Aster, R.H. & Casper, J.T. (1985) T-lymphocyte subpopulations in patients with classical hemophilia treated with cryoprecipitate and lyophylised concentrates. New England Journal of Medicine, 308, 83-86.
14. Morfini, M., Radfanelli, D., Filimberti, E., Cinotti, S., Piazza, E., Longo, G. & Ferrini, P.R. (1989) Protein content and factor VIII complex in untreated, treated and monoclonal factor VIII concentrates. Thrombosis Research, 56, 169-178.
15. + counts before and after switching to monoclonal high-purity factor VIII concentrate in HIV-infected haemophilic patients. Thrombosis and Haemostasis, 72, 214-217.
16. Seremetis, S., Aledort, L., Allaine, J., Bona, R., Bray, C., Eyster, E., Brettler, D., Kessler, C., Lusher, J., Rickles, S & Sacks, H. (1993) A comparison of immune function in HIV seropositive haemophilic patients randomised to treatment with intermediate purity and monoclonally immunopurified factor VIII concentrate. Lancet, 342, 700-703.
17. Steel, C.M., Ludlam, C.A., Beatson, D., Peutherer, J.F., Cuthbert, R.J.G., Simmonds, P., Morrison, H. & Jones, M. (1988) HLA-haplotype A1 B8 DR3 as a risk factor for HIV-related disease. Lancet, i, 1185-1188.
18. U.K. Haemophilia Centre Directors Organisation (UKHCDO) (1992) Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. Blood Coagulation and Fibrinolysis, 3, 205-214.
19. U.K. Haemophilia Centre Directors Organisation (UKHCDO) (1997) Guidelines on therapeutic products to treat haemophilia and other hereditary coagulation disorders. Haemophilia, 3, 63-77.
20. Volberding, P.A., Lagakos, S.W., Koch, M.A., Pettinelli, C., Myers, M.W. & Booth, D.K. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4 positive cells per cubic milimeter. New England Journal of Medicine, 322, 941-949.
21. Wadhwa, M., Dilger, P., Tubbs, J., Barrowcliffe, T., Mahon, B. & Thorpe, R. (1992) Mechanisms of inhibition of T-cell IL-2 secretion by factor VIII concentrates. British Journal of Haematology, 82, 578-583.
22. Wadhwa, M., Dilger, P., Tubbs, J., Mire-Sluis, A., Barrowcliffe, T. & Thorpe, R. (1994) Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood, 84, 2021-2030.